Search
for
Sort by
Research 31–60 of 1000+
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
- Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Dermatologic Adverse Events from Cancer Treatments
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Are Pediatric GLP ‐1 Receptor Agonist Cutaneous Adverse Events Being Overlooked? Emerging Age‐Specific Patterns and Their Implications for Dermatologists
- Machine Learning–Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated with Minoxidil
- Machine Learning–Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated with Minoxidil
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- Association of alopecia areata with COVID-19 vaccination: A vaccine adverse events reporting system analysis
- Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment
- Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- 176 Hair eruption initiates adverse events of EGFR-targeted cancer therapy
- Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial